ARTICLE SUMMARY:
The need for important changes to MDR has been clear since its enactment in 2017. EU authorities have been reluctant to make substantive revisions, content to do nothing more than extend regulatory timelines. Now, however, there seems to be newfound resolve in Brussels to engage in fundamental reforms. Three leading experts on European medtech regulation discuss what possible restructuring could occur and when it might happen.
